1. Home
  2. AKRO vs VECO Comparison

AKRO vs VECO Comparison

Compare AKRO & VECO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • VECO
  • Stock Information
  • Founded
  • AKRO 2017
  • VECO 1945
  • Country
  • AKRO United States
  • VECO United States
  • Employees
  • AKRO N/A
  • VECO N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • VECO Industrial Machinery/Components
  • Sector
  • AKRO Health Care
  • VECO Technology
  • Exchange
  • AKRO Nasdaq
  • VECO Nasdaq
  • Market Cap
  • AKRO 2.1B
  • VECO 1.9B
  • IPO Year
  • AKRO 2019
  • VECO 1994
  • Fundamental
  • Price
  • AKRO $34.45
  • VECO $28.68
  • Analyst Decision
  • AKRO Strong Buy
  • VECO Buy
  • Analyst Count
  • AKRO 7
  • VECO 7
  • Target Price
  • AKRO $43.20
  • VECO $42.14
  • AVG Volume (30 Days)
  • AKRO 550.3K
  • VECO 608.6K
  • Earning Date
  • AKRO 11-08-2024
  • VECO 11-06-2024
  • Dividend Yield
  • AKRO N/A
  • VECO N/A
  • EPS Growth
  • AKRO N/A
  • VECO N/A
  • EPS
  • AKRO N/A
  • VECO 1.35
  • Revenue
  • AKRO N/A
  • VECO $709,094,000.00
  • Revenue This Year
  • AKRO N/A
  • VECO $9.24
  • Revenue Next Year
  • AKRO N/A
  • VECO $9.96
  • P/E Ratio
  • AKRO N/A
  • VECO $21.19
  • Revenue Growth
  • AKRO N/A
  • VECO 9.71
  • 52 Week Low
  • AKRO $13.39
  • VECO $26.71
  • 52 Week High
  • AKRO $37.00
  • VECO $49.25
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 67.35
  • VECO 37.87
  • Support Level
  • AKRO $31.12
  • VECO $28.41
  • Resistance Level
  • AKRO $35.88
  • VECO $31.00
  • Average True Range (ATR)
  • AKRO 1.59
  • VECO 0.88
  • MACD
  • AKRO 0.40
  • VECO 0.04
  • Stochastic Oscillator
  • AKRO 80.96
  • VECO 10.42

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About VECO Veeco Instruments Inc.

Veeco Instruments Inc is a United States-based company that is principally engaged in designing, developing, and manufacturing thin-film process equipment, which is mainly used to produce electronic devices. The company's product categories by market consist of lighting, display, and power electronics; advanced packaging; MEMS and RF; scientific and industrial; and data storage. The lighting, display, and power electronics market accounts for over half of the total revenue. The company offers products and services in the United States; China; Europe, the Middle East, and Africa, or EMEA; and the rest of the world, with overseas markets contributing the majority of total revenue.

Share on Social Networks: